Verapamil

• Hypertension
• Angina
• Supraventricular Tachycardia
• Atrial Fibrillation Rate Control

Verapamil is a non-dihydropyridine calcium channel blocker used for hypertension, chronic stable and vasospastic angina, rate control in atrial fibrillation and atrial flutter, supraventricular tachycardia, and symptom relief in hypertrophic cardiomyopathy. It is also frequently used off-label for migraine prophylaxis and is the recognized first-line preventive for cluster headache.

Mechanism of Action

Verapamil is a phenylalkylamine that selectively blocks L-type voltage-gated calcium channels in cardiac and vascular smooth muscle. Within cardiomyocytes and the cardiac conduction system, it slows sinus node automaticity, prolongs AV nodal conduction, and reduces the rate of force generation — producing meaningful negative chronotropic, dromotropic, and inotropic effects. In vascular smooth muscle, calcium channel blockade leads to arterial vasodilation, lowering systemic vascular resistance and afterload.

The net hemodynamic effect is reduced myocardial oxygen demand from lower wall tension, slower heart rate, and reduced contractility, plus improved oxygen supply through coronary vasodilation. Unlike dihydropyridines such as amlodipine, verapamil's strong cardiac effects make it ideal for rate control and arrhythmia management but problematic in patients with reduced left ventricular systolic function. The closely related agent diltiazem shares many of these properties with somewhat less negative inotropy and is often preferred when heart failure risk is a concern but rate control is still needed.

Verapamil is extensively metabolized by CYP3A4, with substantial first-pass effect that gives the oral formulation a bioavailability of only 10 to 35 percent. This pharmacokinetic profile underlies many of its clinically important drug interactions, both as a substrate (with strong inducers and inhibitors) and as an inhibitor of CYP3A4 itself, which raises plasma levels of co-administered drugs metabolized by that enzyme.

Clinical Use

For rate control in atrial fibrillation, verapamil is a useful alternative to beta-blockers in patients who cannot tolerate them — for instance, those with reactive airway disease — provided LV systolic function is preserved. For chronic stable angina, it is helpful when beta-blockers are contraindicated or insufficient, and it has a particular role in vasospastic (Prinzmetal's) angina because the underlying mechanism is coronary vasoconstriction that responds well to calcium channel blockade. For supraventricular tachycardia, IV verapamil can terminate AVNRT in hemodynamically stable patients who do not respond to vagal maneuvers or adenosine, though IV use is contraindicated in patients with WPW and atrial fibrillation, where it can accelerate conduction down the accessory pathway and precipitate ventricular fibrillation.

Verapamil's migraine prophylaxis use is supported by AAFP and AAN guidance, particularly for cluster headache where it remains the first-line preventive at higher doses than typically used for cardiovascular indications. Patients with secondary pulmonary hypertension generally should not receive verapamil because of its negative inotropic effects on a stressed right ventricle, and patients with heart failure due to coronary artery disease should avoid it when LVEF is reduced — guideline-directed heart failure therapy with carvedilol, metoprolol succinate, or bisoprolol is preferred for rate control in HFrEF. The American College of Cardiology supports a structured approach to hypertension management with several first-line classes; verapamil is not first-line monotherapy in most modern algorithms but remains valuable for selected patients, particularly those with concurrent angina, supraventricular arrhythmias, or migraine. See our cardiovascular care page for our broader approach.

How to Take It

Immediate-release verapamil is given three times daily and is more often used for angina or rate control titration. Extended-release products are taken once daily — usually at bedtime when used for hypertension, since blood pressure surges most prominently in the early morning hours. Extended-release tablets and capsules should be swallowed whole, not crushed or split, since destroying the controlled-release matrix can produce dangerous blood pressure drops or conduction effects.

Constipation is the most common side effect and reflects calcium channel blockade in gastrointestinal smooth muscle. It often improves with adequate fluid, fiber, and physical activity, with polyethylene-glycol added when needed. Avoid grapefruit juice, which substantially raises verapamil levels through CYP3A4 inhibition. Alcohol should be limited because verapamil increases its blood concentration and can amplify hypotension. Patients should be cautious about combining verapamil with beta-blockers — the combination can produce profound bradycardia and AV block, and IV combination is contraindicated. Anyone considering an over-the-counter herbal supplement, particularly St. John's wort (a strong CYP3A4 inducer), should ask first.

Monitoring and Follow-Up

A baseline ECG and assessment of left ventricular function are essential before chronic use, particularly in patients with structural heart disease or symptoms of heart failure. Blood pressure and pulse should be checked at follow-up; bradycardia (heart rate below 50) or symptomatic hypotension warrants dose reduction. Periodic basic metabolic panel and liver enzymes are reasonable, especially in older adults; both are summarized in our understanding blood work overview. Drug levels of digoxin, if co-prescribed, should be monitored closely because verapamil raises digoxin concentrations by 50 to 75 percent. Statin doses — particularly simvastatin — should be capped because of CYP3A4-mediated interactions, with pravastatin or rosuvastatin being safer alternatives because they are not metabolized through CYP3A4. The MedlinePlus verapamil page gives a clear patient handout.

Calcium-channel-blocker-induced peripheral edema is more common with dihydropyridines but can occur with verapamil. If new ankle swelling develops, examine for heart failure rather than assuming it is benign drug-induced edema, and reassess in patients on combination antihypertensive therapy.

For patients using verapamil for migraine or cluster headache prevention, treatment response is judged over weeks to months and rarely shows immediate improvement. Cluster headache prophylaxis often requires verapamil doses well above those used for hypertension; ECG monitoring becomes more important at higher doses because of risk of conduction delay. Patients should keep a headache diary capturing frequency, severity, duration, and triggers to allow objective assessment of benefit.

When verapamil must be discontinued, taper rather than abrupt stop is appropriate for patients with angina or significant hypertension to avoid rebound. For patients on combination antihypertensive regimens, sequential discontinuation of one class at a time helps preserve overall control while identifying which agent was contributing most to either benefit or side effect. Always check pulse and blood pressure before each dose adjustment in elderly or frail patients, and document orthostatic vitals when symptoms suggest hypotension.

Patient education on the difference between rate control and rhythm control is helpful for those with atrial fibrillation. Verapamil controls the ventricular response rate but does not restore sinus rhythm; anticoagulation decisions are driven by stroke risk (CHA2DS2-VASc score) rather than by symptom control, and patients should understand that feeling better on rate control does not eliminate the need for anticoagulation with apixaban, rivaroxaban, warfarin, or other agents when indicated.

Special Populations

In older adults, start at the low end of the dosing range; constipation, bradycardia, and orthostatic hypotension are more common, and falls become an important concern — see our practical guide to fall prevention. Patients with hepatic impairment should receive substantially lower doses — often 30 percent of normal — because clearance is reduced. Renal dose adjustment is generally not needed but cautious dosing is wise in advanced disease. Pregnancy data are limited but the drug has been used for maternal supraventricular tachycardia and gestational hypertension; nitrates and beta-blockers are typically preferred. Verapamil enters breast milk in small amounts and is generally considered compatible with breastfeeding. In children, verapamil is used for SVT but should be avoided IV in infants due to risk of cardiovascular collapse.

When to Contact Your Doctor

Seek emergency care for fainting, severe lightheadedness, chest pain that is new or worsening, profound shortness of breath, or new ankle swelling that progresses rapidly — these may signal heart failure, severe bradycardia, or AV block. New, persistent constipation that is not relieved by usual measures, severe abdominal pain, or signs of bowel obstruction warrant prompt evaluation. Yellowing of the skin or eyes, dark urine, or easy bruising raises concern for hepatic injury and should be reported quickly. Pulse below 50 beats per minute with symptoms (lightheadedness, fatigue, exercise intolerance) deserves a call before the next dose.

If you have questions about verapamil or your treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.